We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Evidence-Based Dermatology: Research Commentary |

The Misperception That Clinical Trial Data Reflect Long-term Drug Safety Lessons Learned From Efalizumab's Withdrawal

Tamar Nijsten, MD, PhD; Phyllis I. Spuls, MD, PhD; Luigi Naldi, MD; Robert S. Stern, MD
Arch Dermatol. 2009;145(9):1037-1039. doi:10.1001/archdermatol.2009.188.
Text Size: A A A
Published online


Commentary on: Press Release: European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab).

The European Medicines Agency


On February 19, 2009, the European Medicines Agency (EMEA) and the Food and Drug Administration (FDA) issued statements about the safety concerns regarding the risk of progressive multifocal leukoencephalopathy (PML) with the use of efalizumab in patients with psoriasis.1,2 That day, the EMEA recommended suspending sales of efalizumab because of an altered risk to benefit ratio and to carefully discontinue this drug in patients using it in the next 3 months. The FDA issued a public health advisory and changed the labeling of efalizumab to include a “black box” warning. On April 8, 2009, the company voluntarily withdrew efalizumab from the US market.2

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Risk to benefit ratio of efalizumab in treatment of psoriasis in 2009. ADR indicates adverse drug reaction; HRQOL, health-related quality of life; PASI-75, 75% reduction in Psoriasis Area and Severity Index; PMS, postmarketing study; and PsA, psoriatic arthritis.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

9 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles